GlaxoSmithKline (GSK) Reports Q1 EPS of GBP0.20
FREE Breaking News Alerts from StreetInsider.com!
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
- Two major earthquakes strike Venezuela, killing at least 32 and injuring hundreds
- Needham Starts NeoVolta (NEOV) at Buy
- Hertz cuts guidance, announces notes and stock offerings, shares sink
- Rockstar Games opens GTA VI pre-orders, priced at $79.99
- Rubio meets Gulf leaders, pledges security amid Iran deal doubts
GlaxoSmithKline (GSK) Receives Positive CHMP Opinion on Umbipro as Umbilical Cord Infection Treatment
April 29, 2016 8:23 AM EDTOn 28 April 2016, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion in accordance with Article 58 of Regulation (EC) No 726/20041 for the medicinal product Umbipro, intended for the prophylaxis of omphalitis (infection of the umbilical cord) in newborn infants. This medicinal product has been developed by GlaxoSmithKline... More
